Amsbio has launched ecoHSA, an animal-free preparation of the human albumin gene, produced in the seeds of Asian Rice (Oryza sativa), that eliminates risk of viral infectious agents in cell cultures.
Commercial human albumin proteins extracted from plasma have multiple and invaluable uses in cell culture work, but regulations now discourage the use of animal components, even in early research studies.
In addition, human- or animal-derived albumin proteins, even those produced in vitro using insect or mammalian cultures, suffer from variable performance due to low yields and/or production complexities.
These factors make the need for a defined, consistent and animal-free HSA more important than ever.
Building on recent advances in seed protein production technologies to turn the rice endosperm into an optimal system for expressing recombinant proteins, ecoHSA offers significant advantages over traditional albumins.
ecoHSA eliminates risk of animal or viral infectious agents in cell cultures and helps comply with FDA recommendations for animal-free components.
Extensively tested in multiple functional studies, ecoHSA has been proven to be similar in structure and biochemical function to native HSA in all tests performed.
Rigorous standards and procedures in the manufacturing process of ecoHSA ensure minimal batch-to-batch variability.
In tests, ecoHSA has been shown to improve the health of cells by acting as a fatty-acid carrier and hydrophobic moiety scavenger.
EcoHSA also extends the life of cell cultures by scavenging toxins, as well as stabilising membrane proteins and maintaining oncotic pressure, thereby providing better cultures and results.
